AI-Empowered Fundus Platform
AI-Empowered Fundus Imaging: Building an Intelligent Platform for Diagnosis, Treatment, and Early Warning of Fundus Diseases
1 other identifier
observational
1,000
1 country
1
Brief Summary
According to estimates by the World Health Organization, approximately half of the global adult population currently suffers from varying degrees of myopia. In urban areas of China, the myopia rate among primary school students has reached about 40%, and can exceed 80% in high school students. The proportion of patients with high myopia (refractive error greater than 600 degrees) is also increasing year by year. This group is more prone to severe visual problems, including an increased risk of complications such as cataracts, glaucoma, and macular degeneration. Pathological myopia is the main risk factor for vision loss caused by high myopia. In such patients, the elongation of the ocular axis leads to local thinning and protrusion of the posterior pole of the eyeball, forming a posterior scleral staphyloma. Posterior scleral staphyloma is the most representative pathological feature of pathological myopia. Local dilation of the choroid leads to thinning and stretching of the retina, which may ultimately cause problems such as macular retinal schisis, seriously affecting vision and even leading to blindness. This project aims to develop a multimodal intelligent screening system by combining the excellent imaging technology and advanced artificial intelligence (AI) of the Optos non-mydriatic ultra-wide-angle laser scanning ophthalmoscope, B-scan ultrasonography ophthalmic diagnostic instrument, and optical coherence tomography (OCT). The system is designed to achieve precise identification and assessment of ocular fundus diseases, especially pathological myopia, and particularly the core condition of posterior scleral staphyloma (PSS). Simultaneously, a vision prediction model will be constructed to assist doctors in formulating personalized diagnosis and treatment strategies, predicting the trend of vision deterioration, and enhancing the effectiveness of early intervention. This system is expected to significantly improve the prevention and control of pathological myopia, reduce the risk of blindness, and play a pivotal role in telemedicine services, benefiting people in remote areas and promoting public health equity and service quality.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2024
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2024
CompletedFirst Submitted
Initial submission to the registry
February 14, 2026
CompletedFirst Posted
Study publicly available on registry
February 20, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
ExpectedFebruary 20, 2026
February 1, 2026
1.4 years
February 14, 2026
February 14, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Data collection outcome
Demographic data clasification of posterior scleral staphyloma visual acuity and imaging data
From October 2024 to April 2026 (Data collection from patients who visited the hospital before October 2024)
Secondary Outcomes (1)
AI modeling Analysis
From April 2026 to October 2026
Study Arms (1)
Cataract patients with posterior staphyloma due to high myopia
Interventions
The patient underwent a complete set of fundus color photography, B-scan ultrasonography, and OCT imaging during the consultation, and preoperative baseline data, including demographic information, health status, ophthalmic history, and ocular biometric parameters, were collected and recorded in detail
Eligibility Criteria
This retrospective study enrolled patients diagnosed with high myopia and posterior staphyloma (PSS) who visited the Department of Ophthalmology, Shanghai Tenth People's Hospital before October 2024. Sample Size:A total of 1,000 patients (600 for training, 200 for validation, and 200 for internal testing) from the hospital cohort, contributing approximately 6,000 multimodal images.
You may qualify if:
- Patients with a diagnosis of cataract and high myopia and posterior staphyloma, who underwent comprehensive ophthalmic examinations including ultra-widefield fundus photography (Optos), B-scan ultrasonography, and optical coherence tomography (OCT). Baseline data, including demographics, health status, ophthalmic history, and ocular biometric parameters, were completely documented.
You may not qualify if:
- Patients with poor-quality images affecting PSS identification, severe coexisting ocular diseases including glaucoma, diabetic retinopathy that cause media opacities, or severe systemic diseases that could interfere with the study outcomes.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shanghai 10th People's Hospital
Shanghai, China
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Resident Physician
Study Record Dates
First Submitted
February 14, 2026
First Posted
February 20, 2026
Study Start
October 1, 2024
Primary Completion
March 1, 2026
Study Completion (Estimated)
December 1, 2026
Last Updated
February 20, 2026
Record last verified: 2026-02